Soros Fund Management - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 169 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2017. The put-call ratio across all filers is 0.59 and the average weighting 0.1%.

Quarter-by-quarter ownership
Soros Fund Management ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q2 2017$218,000
-63.4%
1,800
-50.3%
0.00%
-73.3%
Q3 2016$596,000
-48.4%
3,623
-55.3%
0.02%
-40.0%
Q2 2016$1,156,000
+176.6%
8,100
+189.3%
0.02%
+257.1%
Q4 2015$418,0002,8000.01%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q2 2017
NameSharesValueWeighting ↓
Samsara BioCapital, LLC 640,688$14,787,0002.73%
DeepCurrents Investment Group LLC 416,800$9,620,0000.33%
DUALITY ADVISERS, LP 105,668$2,439,0000.21%
EULAV Asset Management 335,000$7,732,0000.21%
Virtus ETF Advisers LLC 19,375$447,0000.19%
Hennion & Walsh Asset Management, Inc. 135,214$3,121,0000.19%
PDT Partners, LLC 110,592$2,552,0000.18%
KETTLE HILL CAPITAL MANAGEMENT, LLC 70,256$1,622,0000.16%
ALTRINSIC GLOBAL ADVISORS LLC 168,800$3,896,0000.12%
WOODWARD DIVERSIFIED CAPITAL, LLC 8,939$206,0000.12%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders